IU gastroenterologist develops practice guidelines for most prevalent liver disease

June 21, 2012

An Indiana University School of Medicine gastroenterologist led a team of distinguished physicians who developed the first guidelines for diagnosis and management of non-alcoholic fatty liver disease. The guidelines were published simultaneously in the June issues of the journals Hepatology, Gastroenterology and the American Journal of Gastroenterology.

Naga P. Chalasani, M.B.B.S., professor of medicine and director of the Division of Gastroenterology and Hepatology at the IU School of Medicine and a member of IU Health Physicians, said non-alcoholic is expected to become the No. 1 reason for in the next 10 to 15 years.

Dr. Chalasani, who is the lead author of the journal article, said this is the first time practice guidelines have been developed for the condition by the three major medical societies: the American Association for the Study of Liver Diseases, the American College of Gastroenterology and the American Gastroenterological Association.

"Although the condition has been recognized for 100 years, because of the increasing frequency of obesity, diabetes and metabolic syndrome, the prevalence and incidence of non-alcoholic fatty liver disease is rapidly becoming the most common cause of cirrhosis in the United States," Dr. Chalasani said. The disease also can cause and , he said.

Practice guidelines offer evidence-based information to help health care providers diagnose and manage patients with a specific disease. The guidelines can include treatment options, dosage recommendations, information on risk versus benefits, and cost-effectiveness of treatments, and they help standardize medical care.

Guidelines typically are written at a national level by medical associations or government bodies.

Explore further: Frequent moderate drinking of alcohol is associated with a lower risk of fatty liver disease

Related Stories

Recommended for you

Ebola virus mutations may help it evade drug treatment

September 11, 2015

Genetic mutations called "escape variants" in the deadly Ebola virus appear to block the ability of antibody-based treatments to ward off infection, according to a team of U.S. Army scientists and collaborators. Their findings, ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.